Specify a stock or a cryptocurrency in the search bar to get a summary
Revive Therapeutics Ltd
31RRevive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada. Address: The Canadian Venture Building, Toronto, ON, Canada, M5C 1P1
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 31R
Dividend Analytics 31R
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 31R
Stock Valuation 31R
Financials 31R
Results | 2019 | Dynamics |